Design Therapeutics (DSGN) Shares Outstanding (2020 - 2026)

Design Therapeutics has disclosed Shares Outstanding across 7 years of filings, most recently posting $62.4 million for Q1 2026.

• Shares Outstanding for Q1 2026 came in at $62.4 million, up 9.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $62.4 million (up 9.99% YoY), and the FY2025 annual result was $60.4 million, up 6.42% from the prior year.
• Shares Outstanding came in at $62.4 million for Q1 2026 at Design Therapeutics, up from $60.4 million in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $62.4 million in Q1 2026 to a low of $55.6 million in Q1 2022.
• The 5-year median for Shares Outstanding is $56.5 million (2024), against an average of $56.9 million.
• Across the five-year window, Shares Outstanding advanced 0.28% in 2023 and increased 9.99% in 2026, its largest moves.
• Design Therapeutics' Shares Outstanding stood at $55.9 million in 2022, then increased by 1.03% to $56.5 million in 2023, then grew by 0.5% to $56.8 million in 2024, then rose by 6.42% to $60.4 million in 2025, then climbed by 3.38% to $62.4 million in 2026.
• The last three Shares Outstanding figures came in at $62.4 million (Q1 2026), $60.4 million (Q4 2025), and $57.0 million (Q3 2025), per Business Quant data.